

JUN 19. 2003 10:35AM

GW GLOBAL R&D IS

NO. 7352 P. 1

FAX



To USPTO; Examiner G. Shameem, Art Unit 1626

Company

Fax 703-872-9306

From Valerie L. Phillips

Tel 919-483-8223 Fax 919-483-5730

E-mail Vlp47157@gsk.com

Date June 19, 2003 Pages including cover 5
Subject Response to Office Action

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

FAX RECEIVED

JUN 19 2003

GROUP 1600

OFFICIAL

Serial No.: 10/019.976
Filing Date: October 23, 2001
Applicant: Bigham et al.
Title: Imidazoline Derivatives As Alpha-1A Adrenoceptor Ligands

Attached:
Certificate of transmission via facsimile
Response to Office Action
Transmittal Letter

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Response to Office Action is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on June 19, 2003

Valerie L. Phillips
Valerie L. Phillips


The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Received from <919 483 5730> at 6/19/03 10:01:31 AM [Eastern Daylight Time]

TRANSMITTAL LETTER
(General - Patent Pending)Docket No.
PU3650USWIn Re Application Of: **Bigham et al.**Serial No.
10/019,976Filing Date
October 23, 2001Examiner
G. ShamcemGroup Art Unit
1626Title: **Imidazoline Derivatives As Alpha-1A Adrenoceptor Ligands****TO THE COMMISSIONER FOR PATENTS:**Transmitted herewith is: **Response to Office Action**

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

07-1392
SignatureDated: **19 June 2003****Robert H. Brink, Reg. No. 36,094****23347**

PATENT TRADEMARK OFFICE

cc:

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bigham, et al.

Filed: October 23, 2001

Art Unit: 1626

Serial No.: 10/019,976

Examiner: G. Shameem

For: Imidazoline Derivatives As Alpha-1A Adrenoceptor Ligands

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Response

This is in response to the Office Action mailed April 25, 2003.